ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy.

Autor: Soumoy, Laura^1,2 (AUTHOR) laura.soumoy@umons.ac.be, Genbauffe, Aline¹ (AUTHOR), Mouchart, Lena¹ (AUTHOR), Sperone, Alexandra¹ (AUTHOR), Trelcat, Anne¹ (AUTHOR), Mukeba-Harchies, Léa¹ (AUTHOR), Wells, Mathilde³ (AUTHOR), Blankert, Bertrand³ (AUTHOR), Najem, Ahmad⁴ (AUTHOR), Ghanem, Ghanem⁴ (AUTHOR), Saussez, Sven^1,5 (AUTHOR), Journe, Fabrice^1,4 (AUTHOR) fabrice.journe@umons.ac.be

Publikováno v: Cancer Cell International. 1/4/2024, Vol. 24 Issue 1, p1-17. 17p.